<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xml:lang="en" xmlns="http://www.w3.org/1999/xhtml" lang="en">
<!-- NewPage -->
<head>
<title>Overview of brca</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
<meta name="date" content="2016-01-11"/>
<meta name="keywords" content="brca Namespace"/>
<link rel="stylesheet" type="text/css" href="../stylesheet.css" title="Style"/>
</head>
<body>
<script type="text/javascript">
  //<![CDATA[
if (location.href.indexOf('is-external=true') == -1) {
    parent.document.title="shr Reference Model";
}
//]]>
</script>
<noscript>
  <div>JavaScript is disabled on your browser.</div>
</noscript>
<!-- ========= START OF TOP NAVBAR ======= -->
<div class="topNav"><a name="navbar_top"></a><a href="#skip-navbar_top" title="Skip navigation links"></a><a name="navbar_top_firstrow"></a>
  <ul class="navList" title="Navigation">
    <li class="navBarCell1Rev"><a href="../overview-summary.html">Back to overview</a></li>
    <!-- <li class="navBarCell1Rev"><a href="/../" target="_top">Back to shr Website</a></li> -->
  </ul>
  <div class="aboutLanguage"><em><strong>shr Reference Model Version</strong></em><br/>brca</div>
</div>
<a name="skip-navbar_top"></a>
<!-- ========= END OF TOP NAVBAR ========= -->
<div class="contentContainer">
<h2 title="Overview">Overview of brca</h2>
  <p><p>Breast Cancer data elements.</p></p>
  <table class="overviewSummary" border="0" cellpadding="3" cellspacing="0" summary="Elements and Definitions">
    <thead>
      <tr>
        <th class="colFirst" scope="col">Element</th>
        <th class="colLast" scope="col">Description</th>
      </tr>
    </thead>
    <tbody>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="AverageCEP17SignalsPerCell.html">AverageCEP17SignalsPerCell</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Average number CEP17 signals per cell (dual probe only)</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="AverageHER2SignalsPerCell.html">AverageHER2SignalsPerCell</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Average number of HER2 signals per cell</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="BreastCancerCondition.html">BreastCancerCondition</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Diagnosis of cancer originating in the tissues of the breast, and potentially spread to other organs of the body.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="BreastCancerHistologicGrade.html">BreastCancerHistologicGrade</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The Elston Grade/Nottingham Score, representative of the aggressive potential of the tumor. Well differentiated cells (Grade 1) look similar to normal cells and are usually slow growing, while poorly differentiated cells (Grade 3) look very different than normal and are fast-growing.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="BreastClinicalLymphNodeInvolvement.html">BreastClinicalLymphNodeInvolvement</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Clinical assessment of lymph nodes for presence of cancer cells in staging the N category in breast cancer.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="BreastLymphNodeBodyLocation.html">BreastLymphNodeBodyLocation</a>
        </td>
        <td class="colLast">
          <div class="block"><p>A body site specific to the breast lymph node structure.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="BreastLymphNodeInvolvement.html">BreastLymphNodeInvolvement</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Identification of whether tumor cells have extended to the lymph nodes. Formerly known as BreastNodeInvolvementValues</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="BreastPathologicalLymphNodeInvolvement.html">BreastPathologicalLymphNodeInvolvement</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Pathological assessment of lymph nodes for presence of cancer cells in staging the N category in cancers.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="BreastSite.html">BreastSite</a>
        </td>
        <td class="colLast">
          <div class="block"><p>A body site specific to the breast structure.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="BreastSpecimen.html">BreastSpecimen</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Specimen resulting from biopsy or excision of breast and surrounding tissue.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="BreastTNMPathologicStageGroup.html">BreastTNMPathologicStageGroup</a>
        </td>
        <td class="colLast">
          <div class="block"><p>A panel of breast cancer staging information that is performed prior to surgery, based on evidence such as physical examination, imaging, and/or biopsy. The panel includes biomarkers and histologic grade scales used specifically for breast cancer. The panel should not include both a DCISNuclearGrade and a BreastCancerHistologicGrade, since the latter implies an invasive cancer.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="BreastTNMPrognosticClinicalStageGroup.html">BreastTNMPrognosticClinicalStageGroup</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The stage group breast cancer staging information that is performed prior to surgery, based on evidence such as physical examination, imaging, and/or biopsy. The group includes supporting information including T, N, and M categories, as well as prognostic factors (HER2, estrogen, progesterone receptor status, etc.), as related observations. The panel can include one but not both DCISNuclearGrade and a BreastCancerHistologicGrade, since the latter implies an invasive cancer.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="ColdIschemiaTime.html">ColdIschemiaTime</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The time period between the chilling of a tissue or tissue sample and the time it is warmed.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="CompleteMembraneStainingPercent.html">CompleteMembraneStainingPercent</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Percentage of cells with uniform intense complete membrane staining.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="DCISNuclearGrade.html">DCISNuclearGrade</a>
        </td>
        <td class="colLast">
          <div class="block"><p>An evaluation of the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are in the process of dividing or growing. Cancers with low nuclear grade grow and spread less quickly than cancers with high nuclear grade. In breast cancer, nuclear grade is typically evaluated for ductal carcinoma in situ (DCIS) only.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="EstrogenReceptorAverageStainingIntensity.html">EstrogenReceptorAverageStainingIntensity</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The degree or magnitude of staining across positively stained tumor cells on the entire tissue section relative to the intensity of positive controls run with the same batch.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="EstrogenReceptorNuclearPositivity.html">EstrogenReceptorNuclearPositivity</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The percentage of cells that test (stain) positive for the presence of estrogen receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="EstrogenReceptorStatus.html">EstrogenReceptorStatus</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Estrogen receptor alpha is the predominant estrogen receptor expressed in breast tissue and is overexpressed in around 50% of breast carcinomas. ER status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options.
The current approach is that positive/negative designation is a value, even though that value is (in fact) an interpretation of evidence (NuclearPositivity and AverageStainingIntensity).</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="ExtraCapsularExtensionOfNodalTumorStatus.html">ExtraCapsularExtensionOfNodalTumorStatus</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Status for presence of extranodal extension of carcinoma where extranodal extension is the perforation of a cancer through the capsule of a lymph node into the tissue surrounding the node.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="HER2ReceptorStatus.html">HER2ReceptorStatus</a>
        </td>
        <td class="colLast">
          <div class="block"><p>HER2 receptor status. HER2 is a member of the human epidermal growth factor receptor family of proteins and is encoded by the ERBB2 oncogene. HER2 is overexpressed in 20-30% of breast tumors, and is associated with an aggressive clinical course and poor prognosis. HER2 status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="HER2byFISH.html">HER2byFISH</a>
        </td>
        <td class="colLast">
          <div class="block"><p>HER2 receptor status as determined by single-probe or dual-probe Fluorescence In Situ Hybridization (FISH).</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="HER2byIHC.html">HER2byIHC</a>
        </td>
        <td class="colLast">
          <div class="block"><p>HER2 presence in Breast cancer specimen by Immunohistochemistry (IHC).</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="HER2toCEP17Ratio.html">HER2toCEP17Ratio</a>
        </td>
        <td class="colLast">
          <div class="block"><p>HER2 to CEP17 Ratio (dual probe only)</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="LymphNodeMobility.html">LymphNodeMobility</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The degree of mobility of a lymph node or lymph node group upon palpation.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="LymphNodeSamplingMethod.html">LymphNodeSamplingMethod</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The procedure method used to obtain the specimen analyzed for the pathological lymph node involvement.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="LymphNodeSize.html">LymphNodeSize</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Size of the lymph node or lymph node group which is being clinically assessed.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="MammaprintRecurrenceScore.html">MammaprintRecurrenceScore</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Breast cancer genomic signature assay for 10-year risk of distant recurrence score calculated by Mammaprint.
In the United States, MammaPrint can only be used on cancers that are stage I or stage II, invasive, smaller than 5 centimeters, and estrogen-receptor-positive or -negative. Scores range from -1.0 to +1.0, with scores less than 0 indicating high risk, and scores greater than 0 indicating low risk.
The is currently no LOINC code for Mammaprint test.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="MitoticCountScore.html">MitoticCountScore</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The degree of mitotic activity in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Mitotic activity is assessed as the number of mitoses per 10 high power fields (HPF), with increasing mitotic activity being an indicator of more aggressive cancer. The specific scores assigned to the number of mitoses depends on the size of the HPF. For example, for a HPF size of 0.274 mm^2, less than 10 mitoses per 10 HPF gets a score of 1, 10-19 gets a score of 2, and greater than or equal to 20 gets a score of 3. When larger or smaller HPFs are used, the cutoffs for the number of mitoses corresponding to a specific score are adjusted according to published guidelines.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="NuclearPleomorphismScore.html">NuclearPleomorphismScore</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The degree of nuclear pleomorphism (variability of nuclei) in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Increasing degrees of pleomorphism are associated with increasingly aggressive cancers.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="NumberOfLymphNodesWithIsolatedTumorCells.html">NumberOfLymphNodesWithIsolatedTumorCells</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Number of lymph nodes with isolated metatstatic tumor cells examined for the presence of cancer cells</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="NumberOfLymphNodesWithMacrometastases.html">NumberOfLymphNodesWithMacrometastases</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Number of lymph nodes with macrometastases examined</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="NumberOfLymphNodesWithMicrometastases.html">NumberOfLymphNodesWithMicrometastases</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Number of lymph nodes with micrometastases examined</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="NumberOfRegionalLymphNodes.html">NumberOfRegionalLymphNodes</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Number of regional lymph nodes examined for the presence of cancer cells</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="NumberOfSentinelLymphNodes.html">NumberOfSentinelLymphNodes</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Number of sentinel lymph nodes examined for the presence of cancer cells</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="OncotypeDxDCISRecurrenceScore.html">OncotypeDxDCISRecurrenceScore</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The Oncotype DX test for DCIS (Ductal Carcinoma in Situ) breast cancer. Risk scores range from 0 to 100 with the following interpretations: 0-38: Low-Risk, 39-54: Intermediate-Risk, 55+: High-Risk.
No LOINC code currently exists for this test. We are seeking feedback on the value of separating OncotypeDx scores for DCIS and invasive breast carcinomas. Does it make more sense to report the OncotypeDx as a single score, regardless of the type of cancer?</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="OncotypeDxInvasiveRecurrenceScore.html">OncotypeDxInvasiveRecurrenceScore</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The Oncotype DX test for invasive breast cancer examines the activity of 21 genes in a patient’s breast tumor tissue to provide personalized information for tailoring treatment based on the biology of their individual disease. The value from 0 to 100 indicates the estimated risk of recurrence, with the highest risk indicated by a score greater than 31.
No LOINC code currently exists for this test. We are seeking feedback on the value of separating OncotypeDx scores for DCIS and invasive breast carcinomas. Does it make more sense to report the OncotypeDx as a single score, regardless of the type of cancer?</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="ProgesteroneReceptorAverageStainingIntensity.html">ProgesteroneReceptorAverageStainingIntensity</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The degree or magnitude of staining across positively stained tumor cells on the entire tissue section relative to the intensity of positive controls run with the same batch.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="ProgesteroneReceptorNuclearPositivity.html">ProgesteroneReceptorNuclearPositivity</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="ProgesteroneReceptorStatus.html">ProgesteroneReceptorStatus</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Progesterone receptor status is a factor in determining prognosis and treatment options. The value is the percentage of cells that test (stain) positive for the presence of a receptor. The interpretation of positive or negative (found in the interpretation property) is based on the staining percentage, and may take into account the staining intensity.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="ProsignaRecurrenceScore.html">ProsignaRecurrenceScore</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Breast cancer genomic signature assay for 10-year risk of distant recurrence score calculated by Prosigna.
The Prosigna Score is reported on a 0-100 scale (referred to as ROR Score or Risk of Recurrence Score in the literature), which is correlated with the probability of distant recurrence at ten years for post-menopausal women with hormone receptor positive, early stage breast cancer.</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="TotalNumberOfLymphNodesExamined.html">TotalNumberOfLymphNodesExamined</a>
        </td>
        <td class="colLast">
          <div class="block"><p>Total number of lymph nodes examined for the presence of cancer cells</p></div>
        </td>
      </tr>
      
        <tr class="altColor">
      
        <td class="colFirst">
          <a href="TubuleFormationScore.html">TubuleFormationScore</a>
        </td>
        <td class="colLast">
          <div class="block"><p>The degree of glandular differentiation or tubule formation in breast carcinoma is one component of the Nottingham histologic grade, which is a prognostic indicator for patients with breast carcinoma. Less aggressive cancers have more tubule formation.</p></div>
        </td>
      </tr>
    </tbody>
  </table>
</div>
</body>
</html>